Sharepoint Solutions

PRODUCTS

  • The TWIST™ Mini Liposome Extruder System is an all-inclusive modular liposome extrusion system. The intuitive design allows novice and expert users the ability to create liposome particles ranging from 50 nm to 10 um in diameter. With the heat block and extruder base, users have extended liposome creation capabilities and an easy, ergonomic set up. The TWIST™ System is the perfect solution for small scale R&D and liposome exploration projects.

  • Early Phase Experts

    As a full-service contract research organization, Southern Star Research has the knowledge, industry relationships and technical expertise to get your early-phase clinical trial up and running safely and efficiently.

    With a broad range of experience delivering Phase 1 Healthy Volunteer, First in Human, First in Patient and Phase 2 trials, we know just how important it is for your asset to succeed in the early development lifecycle. Our experienced team will help you obtain high-quality data that will appeal to future investors, meet the requirements of international regulatory bodies such as the FDA, EMA, PMDA, and Health Canada, and prepare your product for larger Phase 3 and 4 studies, partnerships, licensing, and sale.

    Whatever your clinical trial needs, we can provide a flexible, bespoke solution that will not only meet your regulatory requirements but also position your product for commercial success.

  • In today’s competitive and capital-constrained cell and gene therapy environment, early decisions around Chemistry, Manufacturing, and Controls (CMC) can make or break a therapy's timeline, cost-efficiency, and eventual approval. Yet many emerging cell therapy companies struggle with CMC strategy until it becomes a bottleneck.

  • Werum PAS-X as a Service delivers a fully managed, cloud-based MES for pharma and biotech, enabling rapid deployment, scalability, cost savings, compliance, and operational efficiency.

  • Industry leading pharmacovigilance solutions from clinical development through post-approval.

WHITE PAPERS AND CASE STUDIES

NEWS